GlobeNewswire: Kiniksa Pharmaceuticals, Ltd. Contains the last 10 of 131 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:41:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/28/2836854/0/en/Kiniksa-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Portfolio-Execution.html?f=22&fvtc=4&fvtv=48180Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution2024-02-28T12:30:00Z<![CDATA[– ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –]]>https://www.globenewswire.com/news-release/2024/02/21/2833097/0/en/Kiniksa-Pharmaceuticals-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-28-2024.html?f=22&fvtc=4&fvtv=48180Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 20242024-02-21T21:01:00Z<![CDATA[HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2023 financial results and recent portfolio execution.]]>https://www.globenewswire.com/news-release/2024/01/04/2803880/0/en/Kiniksa-Pharmaceuticals-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=48180Kiniksa Pharmaceuticals Provides Corporate Update2024-01-04T12:30:00Z<![CDATA[– ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) –]]>https://www.globenewswire.com/news-release/2024/01/02/2802915/0/en/Kiniksa-Pharmaceuticals-to-Present-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=48180Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference2024-01-02T21:01:00Z<![CDATA[HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).]]>https://www.globenewswire.com/news-release/2023/10/31/2770046/0/en/Kiniksa-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Portfolio-Execution.html?f=22&fvtc=4&fvtv=48180Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution2023-10-31T11:30:00Z<![CDATA[– ARCALYST® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth –]]>https://www.globenewswire.com/news-release/2023/10/24/2766001/0/en/Kiniksa-Pharmaceuticals-to-Report-Third-Quarter-2023-Financial-Results-on-October-31-2023.html?f=22&fvtc=4&fvtv=48180Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 20232023-10-24T20:01:00Z<![CDATA[HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8:30 a.m. Eastern Time to report its third quarter 2023 financial results and recent portfolio execution.]]>https://www.globenewswire.com/news-release/2023/07/25/2710316/0/en/Kiniksa-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Portfolio-Execution.html?f=22&fvtc=4&fvtv=48180Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution2023-07-25T11:30:00Z<![CDATA[– ARCALYST® (rilonacept) Q2 2023 net product revenue of $54.5 million –– ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint –– KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024 –– Cash reserves now expected to fund operations into at least 2027 –– Conference call and webcast scheduled for 8:30 am ET today –]]>https://www.globenewswire.com/news-release/2023/07/17/2705178/0/en/Kiniksa-Pharmaceuticals-to-Report-Second-Quarter-2023-Financial-Results-on-July-25-2023.html?f=22&fvtc=4&fvtv=48180Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 20232023-07-17T12:00:00Z<![CDATA[HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution.]]>https://www.globenewswire.com/news-release/2023/06/06/2683298/0/en/Kiniksa-Pharmaceuticals-to-Present-at-Goldman-Sachs-44th-Annual-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=48180Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference2023-06-06T20:01:00Z<![CDATA[HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time).]]>https://www.globenewswire.com/news-release/2023/05/02/2659011/0/en/Kiniksa-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Recent-Portfolio-Execution.html?f=22&fvtc=4&fvtv=48180Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution2023-05-02T11:30:00Z<![CDATA[– ARCALYST® (rilonacept) Q1 2023 net product revenue of $42.7 million –– ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growth at the midpoint –– Final cohort of KPL-404 Phase 2 rheumatoid arthritis trial now enrolling patients; data expected in 1H 2024 – – Cash reserves now expected to fund operations into at least 2026 – – Conference call and webcast scheduled for 8:30 am ET today –]]>